---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-156660"
form_type: "8-K"
ticker: "GRTX"
cik: "0001563577"
company_name: "Galera Therapeutics, Inc."
filed_at: "2024-06-07T23:59:59+00:00"
generated_at: "2026-06-01T05:34:04.742556+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Galera Therapeutics eliminates COO role; stock moves to OTC Pink

## Summary
- COO Robert Beardsley's position eliminated June 4, 2024 to reduce costs.
- Company continues comprehensive review of strategic alternatives.
- Beardsley eligible for severance; expects consulting at ~$400/hour.
- Common stock now quoted on OTC Pink (GRTX); Nasdaq trading suspended.

## SEC filing metadata
- accession: 0001193125-24-156660
- form_type: 8-K
- ticker: GRTX
- cik: 0001563577
- company_name: Galera Therapeutics, Inc.
- filed_at: 2024-06-07T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1563577/000119312524156660/0001193125-24-156660-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1563577/000119312524156660/d472894d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-156660
- JSON: https://secwatch.observer/filing/0001193125-24-156660.json
- Plain text: https://secwatch.observer/filing/0001193125-24-156660.txt

## Key facts
- Executive change
  Robert A. Beardsley departed as Chief Operating Officer at Galera Therapeutics, Inc..
  - Action: position eliminated
  - Role: Chief Operating Officer
  source text: On June 4, 2024, Galera Therapeutics, Inc. (the “Company”) notified Robert A. Beardsley, Ph.D., the Company’s Chief Operating Officer, that his position is being eliminated in order to save costs as the Company continues to undertake a comprehensive review of strategic alternatives for both the Company and its portfolio of dismutase mimetics.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1563577/000119312524156660/0001193125-24-156660-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.